Shares of Omeros Corp. (OMER) are down more than 16% Thursday, following news related to its lead drug candidate Narsoplimab.
What's driving the stock down?
Narsoplimab, proposed for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), was originally assigned a decision date of July 17, 2021 by the FDA.
Now, the decision date has been postponed to October 17, 2021, as the U.S. regulatory agency requires additional time to review the Narsoplimab Biologics License Application.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.